Full text is available at the source.
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
New Use of Glucagon-Like Peptide-1 Receptor Drugs for Treating Fatty Liver Disease Linked to Metabolism Problems
AI simplified
Abstract
1 in 3-4 adult individuals are affected by metabolic dysfunction-associated steatotic liver disease (MASLD).
- Insulin resistance is central to the development of MASLD and metabolic dysfunction-associated steatohepatitis (MASH).
- Higher rates of MASLD (2 in 3) and MASH with fibrosis (1 in 5) are observed in adults with obesity and diabetes.
- Glucagon-like peptide-1 receptor agonists have shown potential in reversing steatohepatitis and reducing cardiovascular risk.
- This class of medication is currently not approved for treating MASLD but is safe for use across varying stages of the disease.
AI simplified